🟢 NanoViricides is trading 7.7% up in pre-market with no clear catalyst identified

NanoViricides is trading at $1.40, up +7.69% in pre-market, with no clear catalyst identified for the September 30 move.

• The company’s fiscal 2026 annual report was filed September 29, but did not attribute the move to the filing.
• Its Phase II Ebola trial enrollment and dosing announcement was issued September 28; available sources do not establish it as the cause.
• Near-flat market indicators do not establish a broad-market explanation.